Stockscreener 앱 받기
56.68
0.30%
-0.17
시간 외 거래:
56.00
-0.68
-1.20%
전일 마감가:
$56.85
열려 있는:
$56.73
하루 거래량:
1.70M
Relative Volume:
0.60
시가총액:
$10.89B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
21.07
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
-0.16%
1개월 성능:
-5.45%
6개월 성능:
-2.51%
1년 성능:
-10.39%
1일 변동 폭
$56.01
$57.33
1주일 범위
$55.50
$58.33
52주 변동 폭
$50.76
$73.51
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
56.68 | 10.92B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.91 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.13 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.75 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
349.58 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-20 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-09-08 | 개시 | H.C. Wainwright | Neutral |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) - Finviz
Double-digit Revenue Growth Till 2030 Drives BioMarin’s (BMRN) Bullish Thesis - Insider Monkey
Double-digit Revenue Growth Till 2030 Drives BioMarin's (BMRN) Bullish Thesis - Finviz
BioMarin to offer $850 million in notes to fund Amicus acquisition By Investing.com - Investing.com Nigeria
BioMarin Plans to Offer $850 Million in Senior Unsecured Notes - Intellectia AI
BioMarin to offer $850 million in notes to fund Amicus acquisition - Investing.com
BioMarin lines up $2B loan, $800M facility for Amicus deal - Stock Titan
10 Cheap Stocks with Huge Upside Potential - Insider Monkey
BioMarin Plans $850M Senior Unsecured Notes Offering - Intellectia AI
Y Intercept Hong Kong Ltd Sells 51,159 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Sector Gamma AS Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Rakuten Investment Management Inc. Acquires New Shares in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Is Quietly Exploding — Is BMRN the Biotech Stock You’re Sleeping On? - AD HOC NEWS
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case - Chartmill
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
BioMarin vets form Mendra to ‘modernize’ rare disease drug development - BioPharma Dive
Ex-BioMarin execs launch Mendra with $82M to 'modernise' rare disease R&D - FirstWord Pharma
Liquidity Mapping Around (BMRN) Price Events - Stock Traders Daily
BioMarin Pharmaceutical (NASDAQ:BMRN) Raised to Buy at Canaccord Genuity Group - MarketBeat
Campbell & CO Investment Adviser LLC Trims Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Biotech Stocks Facing FDA Decision In February 2026 - RTTNews
BioMarin stock rating upgraded by Canaccord Genuity on Amicus acquisition By Investing.com - Investing.com Nigeria
BioMarin stock rating upgraded by Canaccord Genuity on Amicus acquisition - Investing.com UK
BioMarin names new chief accounting officer - MSN
Aug Volume: Is BioMarin Pharmaceutical Inc stock risky to hold nowDividend Hike & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Has $24.48 Million Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is BioMarin (BMRN) Elevating Digital Strategy To Sharpen Its Innovation And Efficiency Edge? - Sahm
Korea’s Ildong promotes Chae Joon Lee to co-CEO - BioCentury
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Zacks.com featured highlights include Universal Health Services, PNC Financial Services, Global Payments and BioMarin Pharmaceutical - The Globe and Mail
BioMarin’s PALace Study: Long-Term Safety Check on Palynziq and What It Means for Investors - TipRanks
11 potential new genetic-disease medicines as BioMarin maps $4B push - Stock Titan
BioMarin drops development of liver, lung disease asset - MSN
A Look At BioMarin Pharmaceutical (BMRN) Valuation After New Chief Digital And Information Officer Appointment - Sahm
Humana Partners With Atlas to Enhance Cancer Care for Seniors - TradingView — Track All Markets
4 Value Stocks to Buy As Wall Street Weighs Trump Policies - The Globe and Mail
BioMarin names Arpit Davé as Chief Digital and Information Officer - The American Bazaar
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com
BMRN or TARS: Which Is the Better Value Stock Right Now? - Yahoo Finance
Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now? - Yahoo Finance
BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference - MarketBeat
BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down - marketscreener.com
BioMarin appoints Arpit Davé as chief digital and information officer By Investing.com - Investing.com Nigeria
Lobbying Update: $30,000 of BIOMARIN PHARMACEUTICAL INC. lobbying was just disclosed - Quiver Quantitative
BioMarin appoints Arpit Davé as chief digital and information officer - Investing.com
Biomarin Pharmaceutical Inc estimates $3.2 billion in total revenues for FYSEC filing - marketscreener.com
BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer - marketscreener.com
BMRN: Strong growth, pipeline progress, and Amicus integration position for sustained double-digit CAGR - TradingView
BioMarin Appoints Arpit Davé Chief Digital and Information Officer - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - MSN
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.49%
4.12%
자본화:
|
볼륨(24시간):